ERBB2 and breast carcinoma: In the randomized, placebo-controlled, phase III ExteNET trial (NCT00878709), the effect of neratinib (240 mg/day) was evaluated in patients (n = 2840) with stage I-III HER2+ breast cancer who had completed neoadjuvant and adjuvant chemotherapy plus trastuzumab up to 2 years prior to randomization; concurrent adjuvant ET was recommended for patients with HR+ disease7.